Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Alnylam Pharmaceuticals
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Office SBP at Screening as follows:
1. ≥155 mmHg and ≤180 mmHg for patients with untreated hypertension
2. ≥145 mmHg and ≤180 mmHg for patients on antihypertensive medications
24-hour mean SBP ≥130 mmHg and ≤160 mmHg by ABPM after at least 4 weeks of run-in
You may not be if
Secondary hypertension, orthostatic hypotension
Elevated potassium \<lower limit of normal (LLN) range or \>5 milliequivalents per liter (mEq/L)
Estimated glomerular filtration rate (eGFR) of \<30 mL/min/1.73m\^2
Received an investigational agent within the last 30 days
Type 1 diabetes mellitus, poorly controlled Type 2 diabetes mellitus, or laboratory evidence of diabetes during screening without known diagnosis of diabetes
History of any cardiovascular event within 6 months prior to randomization
History of intolerance to SC injection(s)
Clareo Health | Zilebesiran as Add-on Therapy in Patients With Hypertension Not Adequately Controlled by a Standard of Care Antihypertensive Medication (KARDIA-2)
